Researchers sought to determine whether subcutaneous daratumumab would require less HCP time and would be a more efficient method for administering the drug.
Researchers sought to determine whether combination therapies with carfilzomib would be feasible for patients with relapsed/refractory multiple myeloma.
Researchers sought to determine whether plasma biomarkers may help enhance CAR-T therapy for patients with multiple myeloma.
Researchers sought to determine the maximum and recommended phase 2 dose for loncastuximab tesirine in patients with B-cell NHL.
Combination therapy of anti-PD-1 camrelizumab plus decitabine led to longer response in patients with relapsed/refractory Hodgkin lymphoma.
Researchers sought to determine factors that may impact infection risk in patients with CLL.
Researchers sought to determine whether adding daratumumab to standard care for patients with multiple myeloma was a cost-effective option.
Researchers sought to determine whether cambinol would have antitumor activity in multiple myeloma cells.
Researchers sought to determine whether dasatinib and nilotinib would be effective second-line therapies for patients with chronic phase CML.
Researchers sought to determine whether molecular characteristics could help predict responses to treatments with venetoclax in patients with relapsed or refractory AML.
